trending Market Intelligence /marketintelligence/en/news-insights/trending/SD6Gk_8OeBW0-oamuEqcGA2 content esgSubNav
In This List

Innovus Pharmaceuticals plans common stock offering

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Innovus Pharmaceuticals plans common stock offering

Innovus Pharmaceuticals Inc. plans to sell common stock and warrants in an underwritten public offering.

The company intends to use the net proceeds from the offering for the commercial launch of allergic rhinitis treatment FlutiCare, working capital and general corporate purposes, including sales and marketing activities, product development and capital expenditures.

H.C. Wainwright & Co. LLC is acting as the exclusive placement agent for the offering.